Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.

Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Müller P, Bachmann MF.

Eur J Immunol. 2005 Jul;35(7):2031-40.

2.

Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.

Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, Horwith G, Pentel PR.

Clin Pharmacol Ther. 2005 Nov;78(5):456-67. Erratum in: Clin Pharmacol Ther. 2006 Apr;79(4):396.

PMID:
16321612
3.

The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.

Wagena EJ, de Vos A, Horwith G, van Schayck CP.

Nicotine Tob Res. 2008 Jan;10(1):213-8. doi: 10.1080/14622200701704921.

PMID:
18188762
4.

Therapeutic vaccines for nicotine dependence.

Maurer P, Bachmann MF.

Curr Opin Mol Ther. 2006 Feb;8(1):11-6. Review.

PMID:
16506520
5.

Preclinical development of a vaccine 'against smoking'.

Cerny EH, Lévy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, Patiny L, Tuchscherer G, Cerny T.

Onkologie. 2002 Oct;25(5):406-11.

PMID:
12415193
6.

[New prospects of nicotine dependence treatment--vaccines].

Goniewicz ML, Koszowski B, Czogała J, Zymełka A.

Przegl Lek. 2006;63(10):1114-8. Review. Polish.

PMID:
17288232
7.

Vaccination against nicotine: an emerging therapy for tobacco dependence.

Maurer P, Bachmann MF.

Expert Opin Investig Drugs. 2007 Nov;16(11):1775-83. Review.

PMID:
17970637
8.

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.

Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, Hennecke F, Sladko K, Jennings GT, Bachmann MF.

J Allergy Clin Immunol. 2006 Jun;117(6):1470-6. Epub 2006 Apr 27.

PMID:
16751015
9.

A critical evaluation of a nicotine vaccine within a self-administration behavioral model.

Moreno AY, Azar MR, Warren NA, Dickerson TJ, Koob GF, Janda KD.

Mol Pharm. 2010 Apr 5;7(2):431-41. doi: 10.1021/mp900213u.

PMID:
20104903
10.

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.

Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, Pfister T, Rettenbacher M, Volk HD, Wagner F, Müller P, Jennings GT, Bachmann MF.

J Hypertens. 2007 Jan;25(1):63-72.

PMID:
17143175
11.

Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation.

Lang R, Winter G, Vogt L, Zurcher A, Dorigo B, Schimmele B.

Drug Dev Ind Pharm. 2009 Jan;35(1):83-97. doi: 10.1080/03639040802192806 .

PMID:
19016059
12.

Anti-nicotine abuse vaccines in the pipeline: an update.

Cerny EH, Cerny T.

Expert Opin Investig Drugs. 2008 May;17(5):691-6. doi: 10.1517/13543784.17.5.691 . Review.

PMID:
18447595
13.

[Expecting the antinicotine vaccine].

Didilescu C.

Pneumologia. 2009 Jul-Sep;58(3):177-8. Romanian.

PMID:
19817315
14.

Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates.

McCluskie MJ, Thorn J, Gervais DP, Stead DR, Zhang N, Benoit M, Cartier J, Kim IJ, Bhattacharya K, Finneman JI, Merson JR, Davis HL.

Int Immunopharmacol. 2015 Dec;29(2):663-71. doi: 10.1016/j.intimp.2015.09.012. Epub 2015 Sep 26.

PMID:
26404190
15.

Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.

Rosenberg JB, De BP, Hicks MJ, Janda KD, Kaminsky SM, Worgall S, Crystal RG.

Hum Gene Ther. 2013 Jun;24(6):595-603. doi: 10.1089/hum.2012.245.

16.

A vaccine for nicotine dependence: targeting the drug rather than the brain.

Pentel P, Malin D.

Respiration. 2002;69(3):193-7.

PMID:
12097758
17.

Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats.

Pentel PR, Dufek MB, Roiko SA, Lesage MG, Keyler DE.

J Pharmacol Exp Ther. 2006 May;317(2):660-6. Epub 2006 Jan 11.

18.

Nicotine conjugate vaccine as a novel approach to smoking cessation.

Ottney AR.

Pharmacotherapy. 2011 Jul;31(7):703-13. doi: 10.1592/phco.31.7.703. Review.

PMID:
21923458
19.

A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats.

Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, Fattom A.

Pharmacol Biochem Behav. 2000 Jan 1;65(1):191-8.

PMID:
10638653
20.

Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.

McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, Benoit M, Robertson K, Kim IJ, Tharmanathan T, Merson JR, Davis HL.

Int Immunopharmacol. 2013 May;16(1):50-6. doi: 10.1016/j.intimp.2013.03.021. Epub 2013 Apr 2.

PMID:
23562759
Items per page

Supplemental Content

Write to the Help Desk